CinFina Announces FDA Clearance of NDA Ph 1 Trial for the Treatment of Obesity
CINCINNATI--(BUSINESS WIRE)--CinRx Pharma, a mosaic of biotechnology companies accelerating transformational new medicines to patients, today announced that the first study participant has been dosed in CinDome Pharma’s Phase 2 envision3D study of deudomperidone (CIN-102) in patients with diabetic gastroparesis. Deudomperidone is a Dopamine 2/3 antagonist with prokinetic and antiemetic effects being evaluated for the chronic treatment of patients who currently have no therapeutic options for long term management. Gastroparesis is a syndrome defined by delayed gastric emptying in the absence of any physical obstruction and symptoms include bloating, nausea, vomiting, postprandial fullness, and early satiety.
CINCINNATI--(BUSINESS WIRE)--CinRx Pharma, a mosaic of biotechnology companies accelerating transformational new medicines to patients, announced today that Gavin Samuels, M.D., M.B.A has assumed the role of Chief Business Officer. In his new role, Gavin will be responsible for leading corporate, strategic and business development and transactions for the CinRx portfolio.
CINCINNATI--(BUSINESS WIRE)--CinRx Pharma, a mosaic of biotechnology companies accelerating transformational new medicines to patients, announced today the first study participant has been dosed in CinFina’s Phase 1 multiple ascending dose (MAD) study of CIN-109. CIN-109 is a novel, long-acting first-in-class growth differentiation factor 15 (GDF-15) analog being developed as a treatment for obesity. CinFina is a subsidiary ‘CinCo’ of CinRx dedicated to developing four novel, first-in-class therapies for obesity and weight loss and its associated co-morbidities. CIN-109 is the first to advance into Phase 1.